Better Late Than Never: Novavax Submits COVID-19 Vaccine to FDA

The protein-based shot could still be used for boosters and in people under the age of 18.

When you think of COVID-19 vaccines, three companies come to mind: Pfizer, Johnson & Johnson, and Moderna. However, according to a recent FiercePharma article, there’s a new vaccine in town. On Monday, Novavax completed its emergency use authorization request with the FDA for its vaccine. The protein-based shot, dubbed NVX-CoV2373, is intended for people 18 and older, and has demonstrated 90% efficacy against symptomatic disease in large trials in the U.S. and Mexico.

It’s unclear whether the vaccine will be used in the U.S., as the country has relied heavily on mRNA shots from Pfizer and Moderna. Despite delays in submitting to the FDA, Novavax did secure conditional marketing authorization in Europe and an emergency use listing from the World Health Organization and in Indonesia and the Philippines. A statement from the company’s CEO noted that they are working with officials “to develop a plan which includes doses, manufacturing, timing and ongoing clinical trial research for boosters and pediatrics to support their pandemic response.

More in Quick Hits